FDA Approves AstraZeneca's Lynparza for Pancreatic Cancer
30 Dicembre 2019 - 08:42AM
Dow Jones News
By Sabela Ojea
AstraZeneca PLC (AZN.LN) said Monday that its pancreatic-cancer
drug Lynparza has been approved by the U.S. Food and Drug
Administration as a first-line maintenance treatment for metastatic
pancreatic cancer.
The British drug maker said the drug has reduced the risk of
disease progression or death by 47% in adult patients whose disease
has not advanced on at least 16 weeks, as the results from the
pivotal Phase 3 POLO trial showed.
The London-listed company said Lynparza is now the only approved
targeted medicine in biomarker-selected patients with advanced
pancreatic cancer.
"Metastatic pancreatic cancer patients have been waiting a long
time for new therapy options for their devastating disease. Today's
approval of Lynparza provides an exciting new treatment option for
patients," Julie Fleshman, President and CEO of Pancreatic Cancer
Action Network, said.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
December 30, 2019 02:27 ET (07:27 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Grafico Azioni Astrazeneca (LSE:AZN)
Storico
Da Feb 2024 a Mar 2024
Grafico Azioni Astrazeneca (LSE:AZN)
Storico
Da Mar 2023 a Mar 2024